Fermi is trading 4.08% down at $5.76, with no clear company-specific August 26 announcement, filing, earnings update, or analyst action identified.
- The decline reverses part of its 6.94% gain on August 25.
- Recent coverage centers on August 13 results: a $25.81 million second-quarter net loss and concerns about the capital-intensive Project Matador buildout.
- Indexes are modestly lower, but biotech strength is not directly relevant to Fermi’s advanced-energy business; the company-level move remains unexplained.